BR0110419A - Esteróides de 3-nitrogênio-6,7-dioxigênio e usos relacionados aos mesmos - Google Patents
Esteróides de 3-nitrogênio-6,7-dioxigênio e usos relacionados aos mesmosInfo
- Publication number
- BR0110419A BR0110419A BR0110419-5A BR0110419A BR0110419A BR 0110419 A BR0110419 A BR 0110419A BR 0110419 A BR0110419 A BR 0110419A BR 0110419 A BR0110419 A BR 0110419A
- Authority
- BR
- Brazil
- Prior art keywords
- nitrogen
- oxygen
- carbons
- silicon
- hydrogen
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000000962 organic group Chemical group 0.000 abstract 2
- 229910052710 silicon Inorganic materials 0.000 abstract 2
- 239000010703 silicon Chemical group 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000006243 carbonyl protecting group Chemical group 0.000 abstract 1
- 229910001882 dioxygen Inorganic materials 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000002923 oximes Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0011—Unsubstituted amino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0047—Nitrogen only at position 2(3)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
- C07J71/0063—Nitrogen and oxygen at position 2(3)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20061700P | 2000-04-28 | 2000-04-28 | |
| PCT/CA2001/000581 WO2001083512A1 (en) | 2000-04-28 | 2001-04-30 | 3-nitrogen-6,7-dioxygen steroids and uses related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0110419A true BR0110419A (pt) | 2004-02-25 |
Family
ID=22742458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0110419-5A BR0110419A (pt) | 2000-04-28 | 2001-04-30 | Esteróides de 3-nitrogênio-6,7-dioxigênio e usos relacionados aos mesmos |
Country Status (33)
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| DK1278763T3 (da) * | 2000-04-28 | 2007-06-11 | Inflazyme Pharm Ltd | 3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil |
| US20050070487A1 (en) * | 2001-04-24 | 2005-03-31 | Nyce Jonathan W. | Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent |
| JP2004534042A (ja) | 2001-05-22 | 2004-11-11 | インフラジム ファーマシューティカルズ リミテッド | ステロイド−５−エン化合物のステロイド−５−エン−７−オン化合物へのアリル酸化、続くヒドロホウ素化および酸化による、６，７−ジヒドロキシステロイドの生成のための方法およびこの方法の中間体 |
| DE60324562D1 (de) | 2002-08-01 | 2008-12-18 | Astellas Pharma Inc | Kaliumabhängiger natrium-calcium-austauscher |
| US20090285900A1 (en) * | 2003-07-31 | 2009-11-19 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20050101545A1 (en) * | 2003-07-31 | 2005-05-12 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20050113318A1 (en) * | 2003-07-31 | 2005-05-26 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20090317476A1 (en) * | 2003-07-31 | 2009-12-24 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| US20050038004A1 (en) * | 2003-07-31 | 2005-02-17 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026882A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026881A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US20090297611A1 (en) * | 2003-07-31 | 2009-12-03 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20090263381A1 (en) * | 2003-07-31 | 2009-10-22 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US20050043282A1 (en) * | 2003-07-31 | 2005-02-24 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026879A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20050026884A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
| US20110209699A1 (en) * | 2003-07-31 | 2011-09-01 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| US20080051382A1 (en) * | 2003-10-20 | 2008-02-28 | Inflazyme Pharmaceuticals Ltd. | Crystalline Forms of 3-Beta-Amino 17-Methylene Androstane-6-Alpha 7-Beta-Diol Hydrochloride |
| CA2542821A1 (fr) * | 2003-10-20 | 2005-04-28 | Inflazyme Pharmaceuticals, Ltd | Formes cristallines du chlorhydrate de 3-beta-amino, 17-methylene, androstane-6-alpha, 7-beta-diol |
| FR2861077B1 (fr) * | 2003-10-20 | 2006-03-03 | Aventis Pharma Sa | Formes cristallines du chlorydrate de 3-beta-amino, 17-methylene, androstane-6-alpha, 7-beta-diol |
| US20090317477A1 (en) * | 2004-03-31 | 2009-12-24 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis |
| US20050222049A1 (en) * | 2004-03-31 | 2005-10-06 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis |
| US20050227927A1 (en) * | 2004-03-31 | 2005-10-13 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis |
| EP2219677A1 (en) * | 2007-11-21 | 2010-08-25 | The Procter & Gamble Company | Preparations, methods and kits useful for treatment of cough |
| JP5655243B2 (ja) * | 2009-10-19 | 2015-01-21 | 国立大学法人 熊本大学 | インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤 |
| ES2857626T3 (es) | 2010-01-15 | 2021-09-29 | Suzhou Neupharma Co Ltd | Ciertas entidades químicas, composiciones y métodos |
| CN103140237A (zh) | 2010-07-09 | 2013-06-05 | 比奥根艾迪克依蒙菲利亚公司 | 因子ix多肽及其使用方法 |
| EP2670763B1 (en) | 2011-02-02 | 2018-08-01 | Suzhou Neupharma Co., Ltd | Certain chemical entities, compositions, and methods |
| WO2013165924A1 (en) | 2012-04-29 | 2013-11-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| TW201427685A (zh) | 2012-09-25 | 2014-07-16 | Biogen Idec Inc | Ｆｉｘ多肽的應用 |
| KR20220110337A (ko) | 2013-03-14 | 2022-08-05 | 에퀴녹스 파머수티칼스 (캐나다) 인코포레이티드 | Ship1 조절제 및 그와 관련된 방법 |
| RU2015143675A (ru) | 2013-03-14 | 2017-04-27 | Экуинокс Фармасьютикалз (Кэнэда) Инк. | Ship1 модуляторы и относящиеся к ним способы |
| EA037906B1 (ru) | 2013-03-15 | 2021-06-04 | Биовератив Терапьютикс Инк. | Препараты полипептида фактора ix |
| CN104744547B (zh) * | 2013-12-27 | 2017-02-15 | 天津医科大学 | 一种抗乳腺癌转移作用的孕甾烷生物碱衍生物及医药用途 |
| US9944590B2 (en) | 2015-06-26 | 2018-04-17 | Aquinox Pharmaceuticals (Canada) Inc. | Crystalline solid forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol |
| US10053415B2 (en) | 2016-01-20 | 2018-08-21 | Aquinox Pharmaceuticals (Canada) Inc. | Synthesis of a substituted indene derivative |
| IL277904B2 (en) | 2018-04-06 | 2024-05-01 | Aquinox Pharmaceuticals Canada Inc | History of indan for use in the treatment of pain and inflammation |
| CN112533905A (zh) | 2018-04-06 | 2021-03-19 | 塔罗制药公司 | 可用于治疗疼痛和炎症的茚衍生物 |
| CN112654632A (zh) | 2018-04-06 | 2021-04-13 | 塔罗制药公司 | 可用于治疗疼痛和炎症的十六氢-1H-环戊二烯并[a]菲衍生物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3682983A (en) * | 1969-11-12 | 1972-08-08 | Klaus Prezewowsky | Preparation of {66 {11 {11 -17 ethinyl steroids |
| US4548922A (en) * | 1983-06-06 | 1985-10-22 | Beth Israel Hospital | Drug administration |
| AU654474B2 (en) | 1990-01-18 | 1994-11-10 | Cura Nominees Pty Ltd | Glycoalkaloids |
| US5877185A (en) | 1991-10-22 | 1999-03-02 | Octamer, Inc. | Synergistic compositions useful as anti-tumor agents |
| CA2086221C (en) | 1992-12-23 | 2003-07-15 | Raymond J. Andersen | Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agent |
| CA2157594A1 (en) * | 1993-03-10 | 1994-09-15 | Leah L. Frye | Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants |
| US5817632A (en) * | 1993-08-16 | 1998-10-06 | Hsia; Jen-Chang | Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| US5856535A (en) * | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
| US6083532A (en) * | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
| WO1996036230A1 (en) | 1995-05-16 | 1996-11-21 | The Salk Institute For Biological Studies | Modulators for new members of the steroid/thyroid superfamily of receptors |
| US5874597A (en) * | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5847172A (en) * | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
| US6060465A (en) | 1997-02-06 | 2000-05-09 | Miljkovic; Dusan | Bile acids and their derivatives as glycoregulatory agents |
| ATE269086T1 (de) | 1998-03-06 | 2004-07-15 | Univ Brigham Young | Antibiotische steroidderivate |
| DK1278763T3 (da) * | 2000-04-28 | 2007-06-11 | Inflazyme Pharm Ltd | 3-Nitrogen-6,7-dioxygensteroider og anvendelser relateret dertil |
-
2001
- 2001-04-30 DK DK01925262T patent/DK1278763T3/da active
- 2001-04-30 BR BR0110419-5A patent/BR0110419A/pt not_active IP Right Cessation
- 2001-04-30 AT AT01925262T patent/ATE353909T1/de not_active IP Right Cessation
- 2001-04-30 DZ DZ013355A patent/DZ3355A1/fr active
- 2001-04-30 YU YU88102A patent/YU88102A/sh unknown
- 2001-04-30 WO PCT/CA2001/000581 patent/WO2001083512A1/en not_active Ceased
- 2001-04-30 JP JP2001580936A patent/JP2003531916A/ja active Pending
- 2001-04-30 ES ES01925262T patent/ES2282247T3/es not_active Expired - Lifetime
- 2001-04-30 HU HU0300908A patent/HUP0300908A2/hu unknown
- 2001-04-30 CA CA002418748A patent/CA2418748A1/en not_active Abandoned
- 2001-04-30 EP EP01925262A patent/EP1278763B1/en not_active Expired - Lifetime
- 2001-04-30 OA OA1200200328A patent/OA12255A/en unknown
- 2001-04-30 EE EEP200200613A patent/EE200200613A/xx unknown
- 2001-04-30 DE DE60126597T patent/DE60126597T2/de not_active Expired - Lifetime
- 2001-04-30 CN CNB018101674A patent/CN1214039C/zh not_active Expired - Fee Related
- 2001-04-30 RU RU2002131941/04A patent/RU2291873C2/ru not_active IP Right Cessation
- 2001-04-30 HR HR20020944A patent/HRP20020944A2/xx not_active Application Discontinuation
- 2001-04-30 PL PL01365798A patent/PL365798A1/xx not_active Application Discontinuation
- 2001-04-30 PT PT01925262T patent/PT1278763E/pt unknown
- 2001-04-30 MX MXPA02010645A patent/MXPA02010645A/es active IP Right Grant
- 2001-04-30 NZ NZ522181A patent/NZ522181A/en unknown
- 2001-04-30 AU AU2001252084A patent/AU2001252084B2/en not_active Ceased
- 2001-04-30 SK SK1569-2002A patent/SK15692002A3/sk unknown
- 2001-04-30 KR KR1020027014524A patent/KR20030045671A/ko not_active Ceased
- 2001-04-30 UA UA2002119460A patent/UA79229C2/uk unknown
- 2001-04-30 IL IL15244801A patent/IL152448A0/xx active IP Right Grant
- 2001-04-30 US US10/258,950 patent/US20040034216A1/en not_active Abandoned
- 2001-04-30 AU AU5208401A patent/AU5208401A/xx active Pending
- 2001-04-30 AP APAP/P/2002/002659A patent/AP1825A/en active
- 2001-04-30 US US09/845,775 patent/US6635629B2/en not_active Expired - Fee Related
-
2002
- 2002-10-24 ZA ZA200208631A patent/ZA200208631B/en unknown
- 2002-10-24 IL IL152448A patent/IL152448A/en not_active IP Right Cessation
- 2002-10-24 NO NO20025106A patent/NO324873B1/no unknown
- 2002-11-19 BG BG107289A patent/BG107289A/bg unknown
- 2002-11-20 MA MA26916A patent/MA25808A1/fr unknown
- 2002-11-22 CO CO02106292A patent/CO5590904A2/es not_active Application Discontinuation
-
2003
- 2003-07-21 US US10/624,946 patent/US7112580B2/en not_active Expired - Fee Related
-
2006
- 2006-07-28 US US11/496,052 patent/US20070060553A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0110419A (pt) | Esteróides de 3-nitrogênio-6,7-dioxigênio e usos relacionados aos mesmos | |
| PE20040937A1 (es) | Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4) | |
| HUP0203122A2 (hu) | Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| BRPI0409185A (pt) | formulações veterinárias anti-helmìnticas tópicas | |
| MX2007006821A (es) | Derivados de 2,4 (4,6) pirimidina. | |
| BR9813835A (pt) | Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica | |
| CA2333703A1 (en) | Isothiazole derivatives useful as anticancer agents | |
| CA2119572A1 (en) | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs | |
| TNSN03110A1 (en) | Azaindoles. | |
| BR0109467A (pt) | Composto derivados de (beta)-aminoácidos cìclicos, composição farmacêutica, método de tratamento de condições ou doenças mediadas por mps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso de composto | |
| FI73678B (fi) | Foerfarande foer framstaellning av farmaceutiskt anvaendbara azabicyklo-oktankarboxylsyror. | |
| MXPA05007496A (es) | Tienopirimidindionas y su uso en la modulacion de enfermedades autoinmunes. | |
| SE9701304D0 (sv) | Compounds | |
| BR0310032A (pt) | Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos | |
| BR0308133A (pt) | Forma polimórfica cristalina de cloridrato de irinotecan | |
| BR0014808A (pt) | Processos de preparação de um composto, e, compostos nitroaromáticos | |
| BRPI0408248A (pt) | derivados azabicìclicos de piridiloximetila e de benzisoxazol | |
| BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
| EP1277744A4 (en) | OXADIAZONE DERIVATIVES WITH ANTIBODY EFFECT | |
| BR9910628A (pt) | Uso de um composto da série da benzofuroxana, composição farmacêutica, e, processos para a preparação de uma formulação parenteral e para o tratamento de um mamìfero, incluindo um ser humano, de doenças cardìacas da coronária | |
| BRPI0517204A (pt) | sulfato de levosalbutamol cristalino (forma i), sulfato de levosalbutamol cristalino (forma ii), sulfato de levosalbutamol cristalino (forma iii), processo para preparar a forma i do sulfato de levosalbutamol cristalino, processo para preparar a forma ii do sulfato de levosalbutamol cristalino, processo para preparar a forma iii do sulfato de levosalbutamol, composição farmacêutica, composto, combinação, pó seco para inalador, processo para preparar um pó seco para inalador, processo para preparar uma composição famacêutica, processo para fabricação de uma composição farmacêutica, método para tratamento de um mamìfero, e uso de uma combinação de salbutamol | |
| MX9200485A (es) | Proceso para la obtencion de derivados de tetra hidro piridina y composicion farmaceutica que los contiene. | |
| JP2005529935A5 (enExample) | ||
| BR9809496A (pt) | Composto, processo para produzi-lo, uso do mesmo, preparação farmacêutica, e, processo para tratar pacientes necessitados de tratamento. | |
| ATE266029T1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |